Advances in treatment of lung cancer with targeted therapy.
about
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.Digoxin downregulates NDRG1 and VEGF through the inhibition of HIF-1α under hypoxic conditions in human lung adenocarcinoma A549 cellsCD24+/CD38- as new prognostic marker for non-small cell lung cancer.Molecular understanding of lung cancers-A review.Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor TherapyCombination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing micePrediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer.Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancerAnti-ABCG2 scFv antibody of lung adenocarcinoma increases chemosensitivity and induces apoptosis through the activation of mitochondrial pathway.Personalized targeted therapy for lung cancerClinicopathological and prognostic significance of metastasis-associated protein 1 expression and its correlation with angiogenesis in lung invasive adenocarcinomas, based on the 2011 IASLC/ATS/ERS classification.Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study GroupClinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India.Genetic testing for respiratory disease: are we there yet?Clinical testing for molecular targets for personalized treatment in lung cancer.Epigenetics in lung cancer diagnosis and therapy.Treatment Outcome of Metastatic Spine Tumor in Lung Cancer Patients: Did the Treatments Improve Their Outcomes?Aurora B expression modulates paclitaxel response in non-small cell lung cancer.Overexpression of the non-coding SOX2OT variants 4 and 7 in lung tumors suggests an oncogenic role in lung cancer.Utility of folate receptor alpha immunohistochemistry in cytology specimens of metastatic breast carcinoma, metastatic serous carcinoma of Müllerian origin, and primary lung adenocarcinoma.Loss of β-arrestin1 expression predicts unfavorable prognosis for non-small cell lung cancer patients.Combined analysis identifies six genes correlated with augmented malignancy from non-small cell to small cell lung cancer.Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control studyFocal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC).Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience.The annoying pulmonary nodule on CT.A validated preoperative score predicting survival and functional outcome in lung cancer patients operated with posterior decompression and stabilization for metastatic spinal cord compression.EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.Prognostic factors in patients with metastatic spine tumors derived from lung cancer-a novel scoring system for predicting life expectancy.
P2860
Q27853015-F900FC7F-1879-46C7-AB25-8FC6E2C2D5AAQ28397747-AE1EE3A0-56EA-43C0-A7C7-B8B7B82A097FQ30446381-EFE86DE9-DE60-4289-94D2-148EA036B00EQ33628898-030BB3A9-5932-4933-96B9-79FACDF7D1EEQ33925570-DB0BADEA-5C85-4DCD-8846-403F17CF2512Q33927165-1467D9CC-161E-4A5E-B281-0BDB85374082Q35833780-D91DDE4A-1E31-4A23-92D3-4425D3A4C23FQ36022297-2F13496D-16FE-41D9-9531-C92AB747A546Q36050053-4A500F4F-0F77-439F-A1AE-D79B32AEC2B6Q36321826-81C59C30-D38D-4DBC-9737-FCFCCA03236AQ36502784-6D40CA68-8252-4450-A634-173BA585C8ADQ36824366-E9B23929-C0E7-415D-BFF1-3F2B8EE795EFQ37651236-036F1E86-E7A3-48B6-954B-7D199DF66F0BQ38034511-2E6E0728-C2E0-4934-98B8-DA09BAE9591CQ38041563-B99DA11A-BDC2-427A-BF32-CBB81777E070Q38457939-5D3B00AB-96A2-40C4-8EBA-A3FDB7AEAACFQ38620380-45D1F207-B01A-4F9D-A701-3666EE195E94Q38720934-10608966-FDF7-4C4A-9B1C-E18EBB7361AEQ38796631-4E6B79B8-DFE4-462D-A1C8-6CCFF7D52529Q39997968-CC17ED2C-4EA4-4517-BDCC-EF418DC4FCBDQ40621763-ED5F961D-97AB-40B7-B848-E14AA0A6A1DEQ41389873-FB8E6527-67DF-4856-8541-DFBF0A30CE80Q42106918-E1AEE715-C880-46CA-9014-425072CF0660Q44951464-155E72BE-A1EF-4910-B4F2-312C97B1D52EQ45210729-C8187966-2587-4C0C-8B91-CFD764230422Q49136595-97EAF429-3BFF-475A-8734-A739FE64924FQ50091853-BF04FBEC-EBEC-4F0A-A32D-862CFA532CEFQ51007370-40C17341-88E0-4518-9FD1-9456865DD06DQ51092453-1A3C9EC7-CEAF-494C-996D-3E1034E1A299Q53298243-B4898D2C-7B72-472C-BCAB-A55C080D527EQ54441930-61790C2D-F418-4370-9521-387B0F4B6040Q55507822-0F21C3FE-7825-4E1E-8319-DA586F837A3E
P2860
Advances in treatment of lung cancer with targeted therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Advances in treatment of lung cancer with targeted therapy.
@en
type
label
Advances in treatment of lung cancer with targeted therapy.
@en
prefLabel
Advances in treatment of lung cancer with targeted therapy.
@en
P1476
Advances in treatment of lung cancer with targeted therapy.
@en
P2093
Lucian R Chirieac
Philip T Cagle
P304
P356
10.5858/ARPA.2011-0618-RA
P577
2012-05-01T00:00:00Z